A novel oxidative-inflammatory biomarker for Parkinson’s disease: clinical utility of the uric acid-to-albumin ratio
Neurological Sciences · 2026-10 · 47 (10)
DOI: 10.1007/s10072-026-09415-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurological Sciences, online erschienen am 07.10.2026. Verfasst von Wenbo Xiu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Translational Clinical Immunology Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, School of Medicine, University of Electro…. Hauptthemen laut MEDLINE: Uric Acid, Parkinson Disease, Oxidative Stress, Serum Albumin. Die Arbeit nennt 39 Literaturangaben. Gefördert von: Sichuan Medical and Health Promotion Association, Provincial Cadre Healthcare Committee Dissemination Grant, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital.
Abstract (Originalsprache)
Background
Emerging evidence highlights the contribution of systemic inflammation and oxidative stress to the pathogenesis and progression of Parkinson’s disease (PD). Accordingly, blood-based biomarkers that capture these processes are of increasing clinical interest. This study evaluated the association between PD and serum uric acid, serum albumin, and their integrated index—the uric acid-to-albumin ratio (UAR)—to determine their potential utility as biomarkers of systemic inflammation, oxidative stress, and disease progression.
Methods
A total of 153 patients with PD and 291 healthy controls were included. Serum uric acid, albumin, and UAR were measured through standardized biochemical assays. Group comparisons and multivariable logistic regression were performed to assess associations with PD, and analyses stratified by Hoehn and Yahr stage examined relationships with disease severity.
Results
Uric acid, albumin, and UAR levels were significantly lower in patients with PD compared with healthy controls (all p < 0.001). After adjustment for age, sex, hypertension, and diabetes, UAR remained independently associated with PD, with lower UAR corresponding to higher odds of disease (OR = 0.72, 95% CI: 0.63–0.82, p < 0.001). Stratified analyses showed that UAR reductions were most prominent in early and middle PD stages, whereas advanced-stage values approximated those of controls. ROC analysis demonstrated moderate discriminative ability of UAR for PD overall (AUC = 0.630) and for early-to-middle stage disease (AUC = 0.620 and 0.644, respectively).
Conclusion
UAR is significantly reduced in PD and associated with early–middle disease stages, supporting its potential as an accessible biomarker for PD monitoring, though larger longitudinal studies are needed for validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational Clinical Immunology Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
- Sichuan Provincial People's Hospital, School of Medicine, Sichuan Provincial Center for Mental Health, University of Electronic Science and Technology of China, Chengdu, China.
- Key Laboratory of Psychosomatic Medicine, Chinese Academy of Medical Sciences, Chengdu, China.
- Health Management Center & Health Management Research Institute, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
- Department of Obstetrics & Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China.
- Translational Clinical Immunology Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China. ken_023@126.com.
Förderung
- Sichuan Medical and Health Promotion Association
- Provincial Cadre Healthcare Committee Dissemination Grant
- Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital
- Chengdu Municipal Science and Technology Program
- Open Project of Sichuan Provincial Key Laboratory for Clinical Immunology Trans-lational Medicine
Zitieren
APA
Xiu, W., Zhang, G., Chen, Y., Sun, C., Gao, Y., Li, A., Zhang, H., Shuai, P., Cheng, J., Wang, J., Xiao, X., & Deng, B. (2026). A novel oxidative-inflammatory biomarker for Parkinson’s disease: clinical utility of the uric acid-to-albumin ratio. Neurological Sciences, 47(10). https://doi.org/10.1007/s10072-026-09415-4
Vancouver
Xiu W, Zhang G, Chen Y, Sun C, Gao Y, Li A, et al. A novel oxidative-inflammatory biomarker for Parkinson’s disease: clinical utility of the uric acid-to-albumin ratio. Neurological Sciences. 2026;47(10). doi:10.1007/s10072-026-09415-4
BibTeX
@article{Xiu2026,
author = {Xiu, Wenbo and Zhang, Gao and Chen, Yang and Sun, Chaonan and Gao, Yanping and Li, An and Zhang, Haiping and Shuai, Ping and Cheng, Jing and Wang, Jinxia and Xiao, Xiao and Deng, Bolin},
title = {A novel oxidative-inflammatory biomarker for Parkinson’s disease: clinical utility of the uric acid-to-albumin ratio},
journal = {Neurological Sciences},
year = {2026},
volume = {47},
number = {10},
doi = {10.1007/s10072-026-09415-4}
}
EUVIMED